Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 20/20 | 0.57 |
| ▸ | CDK2 | P24941 | 20/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 18/20 | 0.57 |
| ▸ | AURKA | O14965 | 11/20 | 0.57 |
| ▸ | PLK1 | P53350 | 8/20 | 0.56 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.56 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.56 |
| ▸ | CDK4 | P11802 | 3/20 | 0.56 |
| ▸ | CCND3 | P30281 | 3/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.56 |
| ▸ | TTK | P33981 | 2/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL20600108 | 0.95 | CCNA2 (0.53) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL31326950 | 0.88 | CCNA2 (0.57) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL10220785 | 0.88 | CCNA2 (0.57) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Potassium Ion SCHEMBL9940757 | 0.86 | CCNA2 (0.44) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL29709987 | 0.85 | CDK2 (0.48) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL9940808 | 0.85 | CCNA2 (0.44) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL10216339 | 0.85 | CCNA2 (0.43) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL9940761 | 0.82 | CCNA2 (0.60) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL3503440 | 0.81 | CCNA2 (0.65) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL16572387 | 0.81 | CCNA2 (0.66) | CCNA2CDK2CCNA1AURKAPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110896636-B | Salts of compounds that inhibit MPS1 kinase, preparation thereof and formulations comprising the same | 内尔维亚诺医疗科学公司 | 2022-07-19 | — | — | CN | claimed |
| CN-116332942-A | Synthesis method of substituted pyrazolo-quinazoline derivative | 合肥工业大学 | 2023-06-27 | — | — | CN | disclosed |
| EP-3645535-A1 | NEW SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]-2-METHOXYPHENYL}AM INO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION AND FORMULATIONS CONTAINING IT | Les Laboratoires Servier SAS (FR) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019002454-A1 | NEW SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]-2-METHOXYPHENYL}AM INO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION AND FORMULATIONS CONTAINING IT | LES LABORATOIRES SERVIER (FR) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019002542-A1 | COMBINATION OF A MPS1 INHIBITOR AND A TAXANE COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | LES LABORATOIRES SERVIER (FR) | 2019-01-03 | — | — | WO | disclosed |
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-2614065-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-07-17 | — | — | EP | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | CCNA2 1765/4885CDK2 113/4885CCNA1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.